Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miro-Breast exploratory study
jRCTs031260048Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mirogabalin in Persistent Pain After Breast Cancer Surgery (PMPS) and Neuralgia (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in pain score. Started Jun 2026; status: recruiting.
02
Drugs
mirogabalin
03
Conditions
Persistent Pain After Breast Cancer Surgery (PMPS)Neuralgia
Beyond the preview
Go deeper on jRCTs031260048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260048.